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1. Introduction
Infectious diseases are closely dependent on the nature and complexity of human behav‐
iour, as they reflect who we are, what we do and how we interact with other people, ani‐
mals and the environment. Worldwide, these diseases remain a leading source of human
morbidity and mortality in all age groups [1]. Their emergence is thought to be driven largely
by socio-economic, environmental and ecological factors [2]. According to Centre for Strate‐
gic and International studies, globally 16% of the deaths each year are from infectious diseases,
this number not only causes huge burden but also produces immense challenge toward
building better healthcare system. The past few years witnessed emergence and re-emer‐
gence of several microbial infections. A majority of them have been vector-borne infections
(especially, the arthropod-borne) viral diseases, which constitute 90% of the re-emerging
diseases [3]. Mosquito-borne Flaviviruses provide some of the most important examples of
emerging and resurging diseases of global significance [4]. Virulent strains of these viruses
are continually evolving and expanding their geographic range, thus rapid and sensitive
screening assays are required to detect emerging viruses and monitor their prevalence and
spread. Diagnostic tests play a major role in the clinical care of patients with infectious diseases,
including detection of specific pathogens, discovery of new pathogens, determining appro‐
priate therapy, monitoring response to therapy, assessing prognosis and disease surveil‐
lance. Whether caring for an individual patient with an infectious disease or responding to a
worldwide pandemic, the rapid and the accurate establishment of a microbial cause is
fundamental to quality care [5].
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2. Flaviviruses
Flaviviruses are responsible for a number of important mosquito-borne diseases of man and
animals globally. These are a highly diverse group of RNA viruses classified within the genus
Flavivirus, family Flaviviridae [6]. Flavivirus includes >70 viruses, which are potent human
pathogens [7]. These viruses are central etiologic agents of human disease, causing clinical
disease ranging from fever to severe manifestations, such as encephalitis and hemorrhagic
fever [8]. They are positive-stranded RNA viruses containing a genome of 10–11 kb. Ge‐
nome is divided into three structural genes—the capsid (C), membrane (M) and envelope (E)
—and seven non-structural (NS) genes—NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 [9].
Growing cases of dengue virus (DV) and Japanese encephalitis virus (JEV) in Asia, recurrent
outbreaks of yellow fever virus (YFV) in Africa and South America and the continuing spread
of West Nile virus (WNV) all through the Americas show the geographical burden of Flavivirus
diseases. These particular viral diseases are a significant burden on global economies and
public health, including the recent Zika virus (ZIKV) and DV diseases, which caused emer‐
gency situation across the globe. Accurate diagnosis and differentiation of the infecting virus
is important, especially in areas where many Flaviviruses are circulating [8].
3. Present flavivirus diagnostic test
Flavivirus diagnosis is often unclear the reason is that the laboratory diagnosis of these viral
infections is based on isolation of the virus, detection of viral RNA using reverse transcription
polymerase chain reaction (RT-PCR), plaque reduction neutralization test (PRNT), haemag‐
glutination and haemagglutination inhibition assays (HI), antibody detection, immunofluor‐
escence assays (IFA) and enzyme immunoassays (EIA), high-throughput, rapid
microneutralisation assays, lateral flow assay (LFA), microsphere immunoassay (MIA),
biosensors and microfluidic systems and autologous red blood cell agglutination assays [10].
Most of these assays results may not declare the specific Flavivirus infection, since most of them
have cross-reactivity or the other issues.
4. Disadvantages of the available tests
The disadvantages of the present available tests include—For PRNT: labour intensive, require
skilled personnel, a minimum of 5 days to perform and the handling of live virus, which
requires a Biosafety level 3 (BSL-3) facilities. For HI: different pH buffers are required for each
different antigen. A constant supply of fresh avian red blood cells is also necessary and there
is a high level of cross-reactivity among the Flaviviruses [11]. For IFA: requirement for a
fluorescent microscope to evaluate the results and cross-reactivity. For enzyme-linked
immunosorbent assay (ELISA): unable to differentiate infections caused by different subtypes
of particular Flavivirus. Accurate diagnosis and differentiation of the infecting virus is impor‐
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tant, especially in areas where many Flaviviruses are circulating. For LFA: sample number
should be small. For MIA: requires specialized equipment [12].
5. Need for rapid diagnosis
One of the major challenges during any outbreak is early diagnosis of infection, which is
difficult because the early symptoms are non-specific toward particular infection and often
are seen in patients with more common diseases [13]. During outbreaks, rapid detection of
pathogens in individual cases is crucial in achieving the best clinical management, public
health surveillance and control outcomes. With the addition of fields such as chemistry,
immunology, molecular biology, biochemistry, nucleic acid amplification and engineering, it
is now possible to determine the specific aetiology of a patient’s infectious disease in the
hospital, clinic, office, remote village or even a patient's home. With automation and highly
multiplexed assays, individual pathogens can be readily identified in a wide variety of
specimen types, including blood, urine, tissue, mucosal swabs, cerebrospinal fluid, respirato‐
ry secretions and stool samples. But one of the major limitations of all present available gold
standard techniques is that they require time, which is not possible in case of deadly infec‐
tious diseases [5]. Therefore, rapid, accurate and accessible detection of infections have to be
done. This has an important role in addressing not only mortality but also the spread of the
disease into the newer areas. Rapid diagnostic tests (RDTs) offer the potential to provide
accurate diagnosis to all at risk populations those unable to access services such as micro‐
scopic and other observation of the specimen. RDTs offer a useful alternative to microscopy.
5.1. Advantages of RDTs
• Personal exposure to patient sample is less.
• Maintaining a specialized laboratory with adequately skilled scientists, technicians and
supportive personnel is not required.
• Very less use of high costly instruments and facilities.
• Resources and reagents requirement is limited.
• Discarding of the RDTs equipment is easy.
5.2. Limitations of RDTs
• Environmental conditions such as temperature and humidity can affect the performance of
RDTs.
• Packaging, transport and storage are important for proper working of RDTs.
5.3. The ideal RDTs
The properties of RDTs kits play an enormous role in determining their utility in the diagnosis
of infectious diseases. The prerequisites of the ideal RDTs include the following:
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• Single step processing of the sample.
• Rapid and accurate results.
• RDTs should be cost-effective and sustainable in the long term.
• They have to replace with standard identification test.
• High sensitivity and specificity.
• Reproducible results.
• Purity and volume of assay sample.
6. Serum components as rapid diagnostic markers during flavivirus
infections
The short vireamic period in infected hosts means that serological assays are often the
diagnostic method of choice. Serum consists of substances that are produced mainly by the
body in response to stress, diseases, pathogens, etc. In case of infectious diseases, a serological
blood test is performed to detect and measure the levels of antibodies or other serum sub‐
stances as a result of exposure to a particular microorganism [14]. Studies on serum proteome,
cytokines and inflammatory markers during specific Flavivirus infection may give us clue for
the development of rapid diagnosis. During Flavivirus infections since most of the cases are
Figure 1. The time taken by the various diagnostic techniques for Flavivirus detection and their medical value. Com‐
pared to all other available techniques rapid diagnosis using serum offers the best approach to detect the specific Flavi‐
virus infection.
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asymptomatic during the early phase of the exposure, if the physician has to relay on techni‐
ques like PRNT, which is a time consuming, then patient may die, as few patients have short
incubation period (Figure 1). Serum biomarker analysis for the particular infection and
immediate treatment can help the patient to recover soon. The present most precise method
for detecting Flavivirus infection is PRNT. Even though this method has great insight into this
particular virus biology and pathogenesis, it has quite a few boundaries as discussed above.
The main weakness that limits the clinical relevance of serological methods (if one is looking
for IgG/IgM) is the broad antigenic cross-reactivity that exists between all Flaviviruses. The
quite specific viral envelope (E) protein neutralizing antibody response may contribute to the
false positive results since the amino acid sequences are more conserved. Hence looking for
serum biomarkers (other than IgM, IgG) for particular infection can help in rapid diagnostics,
least expensive and easy to perform. Here we list out few biomarkers (Figure 2) that are
available till date for the detection of the Flavivirus infections.
Figure 2. The rapid diagnosis procedure: When an individual with suspected Flavivirus infection approaches clinician.
The clinician has to go for specific diagnosis based on the symptoms and travel history of the patient. Here are the
precise serum biomarkers that are upregulated/downregulated during definite infection.
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7. Cholesterol as prognostic biomarker during DV infection
Dengue is a systemic viral infection transmitted between humans by Aedes mosquitoes. DV is
a Flavivirus of global importance, with about four billion people across 128 countries at
possibility of infection, and 96 million clinically apparent cases predictable annually [15–17].
The clinical presentation of acute dengue infection is non-specific. The laboratory confirmation
of dengue infection relies on isolation of the virus in cell culture, the identification of viral
nucleic acid or antigens or the detection of virus specific antibodies [18]. The recent report
suggests that the total serum cholesterol, low density lipoprotein (LDL-C) and high density
lipoprotein (HDL-C) levels can be used as biomarker during dengue infection since these levels
were considerably lower in dengue-positive patients compared to dengue-negative patients.
The LDL-C levels showed larger decrease and thus may contribute to the reduction in total
cholesterol. Liver damage caused by DV infection may possibly contribute to the lower
cholesterol levels. It was also observed that total LDL-C and HDL-C levels were lower in severe
compared to mild dengue. In conclusion, lower total serum cholesterol and LDL-C levels at
presentation were associated with subsequent development of dengue hemorrhagic fever. In
addition, the study also indicates that cholesterol level at presentation may serve as a probable
forecaster of severe dengue [19]. Cholesterol and other routine laboratory markers should be
explored as a lower cost and more sustainable move toward the development of biomarker
that can serve as prognostic marker for dengue viral infection. Another study reported that
serum angiopoietin-2 and soluble vascular endothelial growth factor receptor-2 (VEGFR-2)
showed a strong correlation with the occurrence of plasma leakage in DV infected patients. It
was also suggested they could serve as substitute markers for plasma leakage in patients with
acute DV infection [20]. More work need to be done on these markers to confirm that these can
be used in rapid diagnosis of dengue infection. There is an urgent need for the development
of diagnostic and prognostic tools to identify dengue cases and to provide appropriate
supportive care.
8. Serum cytokine profile as biomarker during WNV infection
WNV is a neurotropic human pathogen that is the causative agent of West Nile fever and
encephalitis. From 1999 to 2012, 37,088 cases were reported to the US-Centers for Diseases
Control, including 1549 fatalities [21]. About one in five people who are infected will develop
a fever with other symptoms. Patients typically develop symptoms between 3 and 14 days
after they are bitten by the infected mosquito. Centers for Disease Control and Prevention as
of September 15, 2015, a total of 46 states in USA have reported WNV infections in people,
birds or mosquitoes. Overall, 708 cases of WNV disease in people have been reported. The
cumulative incidence of WNV infection may include as many as three million people [22]. The
study on serum cytokines found that subjects with a history of severe infection had signifi‐
cantly lower levels of the serum IL-4, whereas asymptomatic subjects had elevated baseline
levels of the IL-4 [23]. The study on serum protein profile of healthy and virus infected
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individual may give us clue on biomarker discovery and to develop serum based diagnosis of
the WNV infection.
9. Diagnosis of St. Louis encephalitis virus
St. Louis encephalitis virus (SLEV) was the leading cause of epidemic Flaviviral encephalitis in
the United States prior to the introduction of WNV in late 1999 [24, 25]. Preliminary diagnosis
is often based on the patient’s clinical features, places and dates of travel, activities and
epidemiologic history of the location where infection occurred. Majority of SLEV infections
remain undiagnosed since the symptoms are like normal flu illness [26]. A standardized IgM
antibody-capture enzyme-linked immunosorbent assay protocol is the only available diagno‐
sis for SLEV infection [27]. This assay serves as a priceless tool for the presumptive diagnosis
of acute SLEV infections and facilitates the processing of many serum samples. But, the major
drawback of this assay is that during the antigen preparation from virus-infected suckling
mouse brain the personnel may expose to infectious agents and hazardous chemicals. In
addition, the procedure for this antigen preparation is time consuming, costly and tedious [28].
Research need to emphasize on development of rapid diagnosis kit that aids on identification
of SLEV at much earlier stage.
10. Serum protein profile as biomarker during JEV infection
According to WHO, global health observatory data repository, there were 4707 reported
number of JEV infection cases in 2014 [29]. Japanese encephalitis (JE) is an acute viral zoonotic
infection of the central nervous system (CNS), which produces meningomyeloencephalitis. It
poses a serious public health problem with an increasing frequency of epidemics and outbreaks
in many parts of the Indian subcontinent and Southeast Asian countries [30, 31]. The prelimi‐
nary diagnosis of JEV is often based on the patient's clinical features, places and dates of travel.
The present laboratory diagnosis of JE is generally accomplished by testing of serum or
cerebrospinal fluid (CSF) to detect virus-specific IgM antibodies. JEV IgM antibodies are
usually detectable 3–8 days after onset of illness and persist for 30–90 days. But the main
weakness that limits the clinical relevance of these methods is the broad antigenic cross-
reactivity that exists between all Flaviviruses and this may contribute to the false positive
results. Serum protein profiles other than antibodies work as potential biomarkers for knowing
disease status. The analysis of serum proteins of patients and healthy individual by surface-
enhanced laser desorption/ionization–time of flight–mass spectrometry (SELDI-TOF-MS) in
combination with the ProteoMiner technology that accurately displays low-abundance
proteins responsible for virus infection could help physicians for rapid diagnosis of JEV
infection [32]. One of the serum factors that could serve as potential biomarker is human
macrophage-derived factor (hMDF) that specifically secreted during JEV infection. The levels
of hMDF in blood will rise to its highest level by second week of infection [33, 34]. Hence, the
detection of hMDF in blood could be a useful prognostic marker of the JEV infection.
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11. Conclusion
The burden of Flaviviral infection is expected to continue to increase in the future due to climate
change, globalization, travel, trade, urbanization, socioeconomics, viral evolution and other
factors. The short incubation time for most of the Flaviviruses infections and no specific
diagnosis make these an important public health problem globally. RDTs methods may be
implemented as adjuncts to the epidemiologic investigation of Flavivirus disease outbreaks.
As sensitivities, specificities, positive predictive value and negative predictive value of RDTs
continue to improve and become more widely appreciated through production of less
expensive and more user-friendly platforms, it will become necessary to formulate responsible
guidelines for the appropriate and optimal use in clinical practice in clarifying infectious
disease diagnoses and improving patient outcomes. There is a critical call for discovery of
serum biomarkers that are specifically present or up-regulated during particular Flavivirus
infection. Recently, there were many reports on micro-RNA (miRNA), which gets upregulated
or downregulated during these particular infections but relaying on miRNA may not be the
right practice since they are regulated by several factors and it involves molecular biology
work and equipment. The advantage of serum analysis is that, it is least expensive, easy to
perform and biosafety practices are not required. Growing cases of Flavivirus infections
globally says that there is a critical need for the development of diagnostic and prognostic tools
to identify specific cases and to provide appropriate supportive care and with anticipation that
one day there will be a specific diagnosis and therapeutics for all Flavivirus infection.
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